Umeclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
Fixed‐dose combination aclidinium/formoterol showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
Aclidinium bromide showed no clear difference in non‐fatal serious adverse events compared with placebo (moderate certainty).
Regular salmeterol showed no clear difference in all‐cause non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ children compared with placebo (moderate certainty).
Regular salmeterol leads to higher all‐cause non‐fatal serious adverse events ‐ adults and adolescents compared with placebo (high certainty).
Regular salmeterol showed no clear difference in asthma‐related non‐fatal serious adverse events ‐ adults and… compared with placebo (low certainty).